Why Is Neil Woodford So Confident About GlaxoSmithKline plc?

Neil Woodford has put 6% of his funds under management into GlaxoSmithKline (LSE: GSK), and when you look at the headline dividend yield it’s easy to see why. However, the company does face some challenges if it’s to be the sort of long-term cash generator this fund manager loves to buy and hold… Find out more in the investing video below!

Elsewhere in the market, the Fool's experts believe sales could treble in just five years at this e-commerce stealth attack whose maverick CEO may have been underestimated by the City.

More details of this exciting FTSE 100 opportunity are available in a brand-new report, "3 Hidden Factors Behind This Daring E-commerce Play". For more free information on this daring buy, click here now.

Owain Bennallack owns shares in GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.